Hyloris Follows On Transaction Scrutiny With Maxigesic IV Updates

The Company’s Partner Secured A Further Deal In Brazil

Following its recently announced leadership changes, Hyloris has made two announcements linked to the marketing of its combined pain therapy Maxigesic IV in Brazil and the US.

Image of Brazilian flag
• Source: Shutterstock

Despite its recently announced leadership changes spurred by continued scrutiny over one of its acquisitions, Hyloris has managed to secure another agreement that will bring its combined pain relief drug Maxigesic IV (paracetamol/ibuprofen) into Brazil.

Established through Hyloris’ partner AFT Pharmaceuticals, the agreement granted exclusive licensing and distribution rights to Brazilian pharma Halex Istar.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Value Added Medicines

More from Products